Literature DB >> 11316173

Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure.

J O Clemmesen1, J Kondrup, L B Nielsen, F S Larsen, P Ott.   

Abstract

OBJECTIVE: In acute liver failure (ALF), urea production is severely impaired, and detoxification of ammonia by glutamine synthesis plays an important protective role. The aim of this study was to examine the effects of therapeutic high-volume plasmapheresis (HVP) on arterial concentrations and splanchnic exchange rates of ammonia, urea, and amino acids-in particular, glutamine.
METHODS: A quantity of 8 L of plasma was exchanged over the course of 7 h in 11 patients with ALF after development of hepatic encephalopathy grade III-IV. Splanchnic exchange rates of ammonia, urea, and amino acids were measured by use of liver vein catheterization.
RESULTS: HVP removed ammonia and glutamine at a rate of 1 micromol/min and 27 micromol/min, respectively. Arterial ammonia decreased from 160 +/- 65 to 114 +/- 50 micromol/L (p < 0.001). In contrast, arterial glutamine was only minimally changed from 1791 +/- 1655 to 1764 +/- 1875 micromol/L (NS). This implied that the rate of systemic glutamine synthesis was increased by 27 micromol/min. Splanchnic exchange rates (before vs after HVP) were as follows: for ammonia, -93 +/- 101 versus -70 +/- 80 micromol/min (NS); urea-nitrogen, 0.08 +/- 1.64 versus -0.31 +/- 0.45 mmol/min (NS); alanine, -73 +/- 151 versus 12 +/- 83 micromol/min (p < 0.05); and glutamine: 132 +/- 246 versus 186 +/- 285 micromol/min (NS), with negative values denoting release.
CONCLUSIONS: Arterial ammonia decreased during HVP in patients with ALF. The data suggest that this effect of HVP could be explained by increased hepatic urea synthesis and possibly by increased glutamine synthesis in muscle tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316173     DOI: 10.1111/j.1572-0241.2001.03706.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

Review 1.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

Review 2.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 3.  Extracorporeal liver support.

Authors:  Jan Stange
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

Review 4.  Liver support systems: will they ever reach prime time?

Authors:  Rafael Bañares; María-Vega Catalina; Javier Vaquero
Journal:  Curr Gastroenterol Rep       Date:  2013-03

Review 5.  The role of plasmapheresis in critical illness.

Authors:  Trung C Nguyen; Joseph E Kiss; Jordana R Goldman; Joseph A Carcillo
Journal:  Crit Care Clin       Date:  2012-07       Impact factor: 3.598

Review 6.  Management of patients with fulminant hepatic failure and brain edema.

Authors:  Flemming Toftengi; Fin Stolze Larsen
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 8.  Clinical application of bioartificial liver support systems.

Authors:  Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Acute liver failure: Summary of a workshop.

Authors:  William M Lee; Robert H Squires; Scott L Nyberg; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Assessment of resin perfusion in hepatic failure in vitro and in vivo.

Authors:  Ying-Jie Wang; Ze-Wen Wang; Bing-Wei Luo; Hong-Ling Liu; Hong-Wei Wen
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.